G01N 2333/4748
P53
Official title: p53
G01N2333/4748 (P53) appears on 53 US grants and 113 published applications in this corpus.
Search patents in G01N- Granted patents
- 53
- Published applications
- 113
- Assignees
- 83
- Inventors
- 229
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 3 |
| 2009 | 1 | 6 |
| 2010 | 1 | 5 |
| 2011 | 3 | 2 |
| 2012 | 5 | 7 |
| 2013 | 2 | 3 |
| 2014 | 4 | 7 |
| 2015 | 1 | 8 |
| 2016 | 5 | 7 |
| 2017 | 2 | 13 |
| 2018 | 4 | 5 |
| 2019 | 4 | 8 |
| 2020 | 5 | 6 |
| 2021 | 3 | 6 |
| 2022 | 3 | 6 |
| 2023 | 2 | 5 |
| 2024 | 1 | 6 |
| 2025 | 3 | 5 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof28 Apr 2026US 12,612,402 B2Nutshell Therapeutics (Shanghai) Co., Ltd.
- T cell receptors recognizing R175H or Y220C mutation in P5325 Nov 2025US 12,479,902 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Methods and compositions for determining the functional activity of DNA double strand break repair pathway molecules for assessing germline risk of cancer18 Mar 2025US 12,253,524 B2Albert Einstein College of Medicine
- Delta133P53Beta and Delta133P53Gamma isoforms are biomarkers of cancer stem cells18 Feb 2025US 12,227,767 B2Centre National de la Recherche Scientifique (CNRS)
- Methods for treatment of patients with myelodysplastic syndromes10 Sep 2024US 12,083,192 B2Actinium Pharmaceuticals, Inc.
- U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease13 Aug 2026US 2026/0235628 A1
- P53 isoform variant for diagnosing cancer2 Apr 2026US 2026/0092923 A1Tuning Fork Bio, Inc.
- Methods and compounds for restoring mutant p53 function29 Jan 2026US 2026/0027097 A1Pmv Pharmaceuticals, Inc.
- Models for predicting mutant p53 fitness and their implications in cancer therapy16 Oct 2025US 2025/0322927 A1Icahn School of Medicine at Mount Sinai
- Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof2 Oct 2025US 2025/0304578 A1Nutshell Therapeutics (Shanghai) Co., Ltd.
Most cited
By later US patents
- Diagnostic panel of cancer antibodies and methods for use77US 8,216,789 B2University of Washington · 2012
- P53 modulator and cancer target34US 8,211,635 B2Board of Regents, The University of Texas System · 2012
- Modulating apoptosis28US 7,638,485 B2Cleveland BioLabs, Inc. · 2009
- Modulating apoptosis28US 8,106,005 B2The Cleveland Clinic Foundation · 2012
- Methods for determining chemosensitivity of cancer cells based upon expression of negative and positive signal transduction factors16US 6,521,407 B1Theryte Limited · 2003